Begins Coverage on Kamada (NASDAQ:KMDA) started coverage on shares of Kamada (NASDAQ:KMDAGet Rating) in a report issued on Monday morning. The firm issued a buy rating on the biotechnology company’s stock.

Separately, Zacks Investment Research cut shares of Kamada from a buy rating to a hold rating in a research note on Tuesday, January 25th.

NASDAQ:KMDA opened at $5.85 on Monday. Kamada has a fifty-two week low of $5.11 and a fifty-two week high of $6.96. The stock has a market capitalization of $260.44 million, a P/E ratio of -116.98 and a beta of 1.05. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.16 and a current ratio of 2.41. The company’s 50-day simple moving average is $5.76 and its 200-day simple moving average is $5.95.

Kamada (NASDAQ:KMDAGet Rating) last released its quarterly earnings results on Tuesday, March 15th. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.09). Kamada had a negative net margin of 2.15% and a negative return on equity of 0.91%. The firm had revenue of $31.47 million during the quarter, compared to the consensus estimate of $22.24 million. During the same quarter in the prior year, the business posted $0.04 earnings per share. On average, research analysts forecast that Kamada will post 0.14 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in KMDA. Marshall Wace LLP acquired a new stake in Kamada in the 1st quarter worth approximately $276,000. Morgan Stanley lifted its stake in Kamada by 10.7% during the 2nd quarter. Morgan Stanley now owns 206,619 shares of the biotechnology company’s stock valued at $1,203,000 after acquiring an additional 19,953 shares during the period. Millennium Management LLC acquired a new stake in Kamada during the 2nd quarter valued at approximately $73,000. Seizert Capital Partners LLC lifted its stake in Kamada by 66.4% during the 3rd quarter. Seizert Capital Partners LLC now owns 156,175 shares of the biotechnology company’s stock valued at $828,000 after acquiring an additional 62,345 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Kamada by 24.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 49,564 shares of the biotechnology company’s stock valued at $263,000 after acquiring an additional 9,701 shares during the period. Institutional investors own 20.41% of the company’s stock.

About Kamada (Get Rating)

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates in two segments, Proprietary Products and Distribution. The company offers Glassia for use in chronic augmentation and maintenance therapy in adults with emphysema due to AATD, KAMRAB/KEDRAB a plasma-derived hyper- immunoglobulin for prophylactic treatment against rabies infection.

Featured Articles

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with's FREE daily email newsletter.